In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eikon Therapeutics, Inc.

http://www.eikontx.com/

Latest From Eikon Therapeutics, Inc.

Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease

Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.

Deal Watch Business Strategies

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies

Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle

Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.

Financing Innovation

Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs

Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.

Financing Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register